{"success":true,"data":{"pressRelease":{"id":"131547","rtpr_id":"nGNX43WzFM","ticker":"LFWD","exchange":"NASDAQ","all_tickers":["LFWD","2RW"],"title":"Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer","author":"Globe Newswire","published_at":"2026-08-31T20:15:00.129Z","article_body":"HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) --\nLifeward Ltd\n(https://www.globenewswire.com/Tracker?data=OLJgUkJYlI_hxy1DPCApkCTMdtQvWeq8DFdrOV7wzpfL8-w6Rrop6U5FQlf6BFOEQJNZfOeb9NVz2Cj19eR93A==).\n(Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical\ninnovation company with a portfolio of commercialized neurorehabilitation\nproducts and a biomedical pipeline, today announced the appointment of Josh\nHexter as Interim Chief Executive Officer effective September 1, 2026 and Rami\nAviram as Chief Financial Officer effective November 1, 2026.\n\nHexter succeeds Mark Grant, who has chosen to leave Lifeward to pursue other\nopportunities after leading the development and implementation of the\nCompany’s current commercial strategy. Grant will serve as a consultant with\nthe Company through September 30, 2026 to work closely with Hexter and the\nleadership team to ensure a smooth transition.\n\nLifeward enters this leadership transition with growing commercial momentum\nand a strategy focused on scaling its rehabilitation business through its\nestablished reimbursement infrastructure and capital-efficient distribution\nmodel. In the second quarter of 2026, revenue increased 16% year-over-year to\n$6.6 million, the Company’s strongest quarterly revenue performance since\nthe fourth quarter of 2024, with ReWalk(® )Personal Exoskeleton sales\nincreasing 13% and AlterG(® )product and service revenue increasing 25%.\n\n“Mark, Almog and the entire Lifeward team have done an outstanding job\nestablishing the foundation for the Company’s next stage of growth,” said\nAvi Gabay, Chairman of Lifeward. “The Company’s second-quarter performance\nprovides tangible evidence of that progress, and we thank them for their\nleadership and important contributions.”\n\nMark Grant, outgoing Chief Executive Officer of Lifeward, commented, “When I\njoined Lifeward, my priority was building the commercial foundation to scale\nthe business: strengthening our reimbursement capabilities, expanding our\ndistribution model and positioning the Company with the capital to execute its\ngrowth strategy. With that foundation in place and delivering results, I have\ndecided to pursue other opportunities. I am proud of what our team\naccomplished and confident Josh, Rami and the Board will build on this\nmomentum.”\n\nHexter brings nearly three decades of leadership, business development,\noperations and management experience in the life sciences industry. His\nexperience includes serving as Chief Operating and Business Officer of Oramed\nPharmaceuticals, Chief Business Officer of BrainsWay, Executive Director of\nCorporate In-Licensing at BioLineRx, and leadership roles in private equity\nand venture capital. He also founded and served as Chief Executive Officer of\nBiosensor Systems Design.\n\n“Lifeward has reached an important point in its development, with the\ncommercial infrastructure, reimbursement foundation and distribution strategy\nin place to support a much larger business,” said Josh Hexter, incoming\nInterim Chief Executive Officer of Lifeward. “Mark built Lifeward’s\ncommercial and reimbursement infrastructure and successfully expanded its\ndistribution model, putting the Company in a strong position to scale from\nhere. My priority as Interim CEO will be to build on the Company’s\nestablished commercial execution strategy and leverage Lifeward’s platform\nacross its growing portfolio of rehabilitation technologies.”\n\nAviram brings a track record of building finance functions at global\ntechnology and medical device companies through periods of growth. He most\nrecently served as Chief Financial Officer of Beewise, a robotics, artificial\nintelligence and computer vision company. He previously served as Chief\nFinancial Officer of ENDYMED Medical and held senior finance leadership\npositions at Syneron-Candela. Aviram is a certified public accountant and\nholds a B.Sc. in Information Systems and Economics and an M.A. in Economics\nfrom the University of Haifa.\n\nAbout Lifeward\n\nLifeward is a global innovator focused on advancing medical technologies and\nbiomedical solutions that improve lives. The Company’s established portfolio\nincludes market-leading neurorehabilitation technologies such as the ReWalk(®\n)Exoskeleton, AlterG(® )Anti-Gravity system, MyoCycle(® )FES System, and\nReStore(® )Exo-Suit. These solutions span the continuum of care in physical\nrehabilitation and recovery, deploying the most advanced robotics and AI\ntechnologies to restore full health and quality of life to a broadening\npatient population. The Company is now executing a strategic evolution into a\ndiversified biomedical company, expanding beyond rehabilitation and into\nhigh-value therapeutic platforms. This includes its Protein Oral Delivery\n(POD™) platform, designed to enable oral delivery of biologic drugs, with\nlead candidate ORMD-0801 (oral insulin) targeting a large and underserved\ndiabetes market.\n\nLifeward has operations in the United States, Israel, and Germany. For more\ninformation on the Lifeward mission and product portfolio, please\nvisit GoLifeward.com\n(https://www.globenewswire.com/Tracker?data=ioeg6IOJEPkYanqwOqbbYPkr0w_8MxAOUSTbXMbnGkECpgnNM0t_Yi7MGS3tXhgHifHCOCtf8HH6o2BSJlwUKw==).\n\nLifeward(®), ReWalk(®), ReStore(® )and AlterG(® )are registered trademarks\nof Lifeward Ltd. and/or its affiliates.\n\nForward-Looking Statements\nIn addition to historical information, this press release contains\nforward-looking statements within the meaning of the U.S. Private Securities\nLitigation Reform Act of 1995, Section 27A of the U.S. Securities Act of\n1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such\nforward-looking statements may include projections regarding the Company's\nfuture performance and other statements that are not statements of historical\nfact and, in some cases, may be identified by words like \"anticipate,\"\n\"assume,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"future,\" \"will,\" \"should,\"\n\"would,\" \"seek\" and similar terms or phrases. For example, when the Company\ndiscusses its momentum, strategy, potential growth and ability to identify a\npermanent chief executive officer, it is using forward-looking statements. The\nforward-looking statements contained in this press release are based on\nmanagement's current expectations, which are subject to uncertainty, risks and\nchanges in circumstances that are difficult to predict and many of which are\noutside of the Company’s control. Important factors that could cause the\nCompany’s actual results to differ materially from those indicated in the\nforward-looking statements include, among others: management’s expectations,\nhopes, beliefs, intentions or strategies regarding the future including,\nwithout limitation, statements regarding: the future operations of Lifeward,\nincluding research and development activities; the nature, strategy and focus\nof Lifeward; Lifeward’s ability to successfully integrate Oratech\nPharmaceuticals Ltd. into its organization and realize the anticipated\nbenefits therefrom; anticipated clinical drug development activities and\nrelated timelines, and other clinical results; the sufficiency of\npost-transaction resources to support the advancement of Lifeward’s pipeline\nthrough certain milestones and the time period over which Lifeward’s\npost-transaction capital resources will be sufficient to fund its anticipated\noperations; unexpected costs, charges or expenses resulting from the strategic\ntransaction; expected timing and results of the ORMD-0801 clinical trial;\nlegislative, regulatory, political and economic developments; the acceptance\nof the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients;\nuncertainties associated with future clinical trials and the clinical\ndevelopment process, the product development process and FDA regulatory\nsubmission review and approval process; the Company's ability to have\nsufficient funds to meet certain future capital requirements, which could\nimpair the Company's efforts to develop and commercialize existing and new\nproducts; the Company's ability to maintain and grow its reputation and the\nmarket acceptance of its products; the Company's ability to achieve\nreimbursement from third-party payors, including CMS, for its products; the\nCompany's limited operating history and its ability to leverage its sales,\nmarketing and training infrastructure; the Company's expectations as to its\nclinical research program and clinical results; the Company's expectations\nregarding future growth, including its ability to increase sales in its\nexisting geographic markets and expand to new markets; the Company’s ability\nto continue to operate as a going concern; the Company's ability to obtain\ncertain components of its products from third-party suppliers and its\ncontinued access to its product manufacturers; the Company’s ability to\nnavigate any difficulties associated with moving production of its AlterG\nAnti-Gravity Systems to a contract manufacturer and transitioning the\nmanufacturing of its ReWalk products to its in-house manufacturer; the\nCompany's ability to improve its products and develop new products; the\nCompany's compliance with medical device reporting regulations to report\nadverse events involving the Company's products, which could result in\nvoluntary corrective actions or enforcement actions such as mandatory recalls,\nand the potential impact of such adverse events on the Company's ability to\nmarket and sell its products; the Company's ability to gain and maintain\nregulatory approvals; the Company's ability to maintain adequate protection of\nits intellectual property and to avoid violation of the intellectual property\nrights of others; the risk of a cybersecurity attack or breach of the\nCompany's IT systems significantly disrupting its business operations; the\nCompany's ability to use effectively the proceeds of its offerings of\nsecurities; and other factors discussed under the heading \"Risk Factors\" in\nthe Company’s annual report on Form 10-K, as amended, for the year\nended December 31, 2025 filed with the SEC and other documents\nsubsequently filed with or furnished to the SEC. Any forward-looking\nstatement made in this press release speaks only as of the date hereof.\nFactors or events that could cause the Company’s actual results to differ\nfrom the statements contained herein may emerge from time to time, and it is\nnot possible for the Company to predict all of them. Except as required by\nlaw, the Company undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\ndevelopments or otherwise.\n\nContact:\nAlmog Adar\nChief Financial Officer\nLifeward\n\nE: media@golifeward.com\nE: ir@golifeward.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX43WzFM","title":"Lifeward Appoints Josh Hexter Interim Chief Executive Officer and Rami Aviram Chief Financial Officer","author":"Globe Newswire","ticker":"LFWD","created":"2026-08-31T20:15:00.129Z","tickers":["LFWD","2RW"],"exchange":"NASDAQ","article_body":"HUDSON, Mass. and YOKNEAM ILLIT, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) --\nLifeward Ltd\n(https://www.globenewswire.com/Tracker?data=OLJgUkJYlI_hxy1DPCApkCTMdtQvWeq8DFdrOV7wzpfL8-w6Rrop6U5FQlf6BFOEQJNZfOeb9NVz2Cj19eR93A==).\n(Nasdaq: LFWD) (“Lifeward” or the “Company”), a diversified biomedical\ninnovation company with a portfolio of commercialized neurorehabilitation\nproducts and a biomedical pipeline, today announced the appointment of Josh\nHexter as Interim Chief Executive Officer effective September 1, 2026 and Rami\nAviram as Chief Financial Officer effective November 1, 2026.\n\nHexter succeeds Mark Grant, who has chosen to leave Lifeward to pursue other\nopportunities after leading the development and implementation of the\nCompany’s current commercial strategy. Grant will serve as a consultant with\nthe Company through September 30, 2026 to work closely with Hexter and the\nleadership team to ensure a smooth transition.\n\nLifeward enters this leadership transition with growing commercial momentum\nand a strategy focused on scaling its rehabilitation business through its\nestablished reimbursement infrastructure and capital-efficient distribution\nmodel. In the second quarter of 2026, revenue increased 16% year-over-year to\n$6.6 million, the Company’s strongest quarterly revenue performance since\nthe fourth quarter of 2024, with ReWalk(® )Personal Exoskeleton sales\nincreasing 13% and AlterG(® )product and service revenue increasing 25%.\n\n“Mark, Almog and the entire Lifeward team have done an outstanding job\nestablishing the foundation for the Company’s next stage of growth,” said\nAvi Gabay, Chairman of Lifeward. “The Company’s second-quarter performance\nprovides tangible evidence of that progress, and we thank them for their\nleadership and important contributions.”\n\nMark Grant, outgoing Chief Executive Officer of Lifeward, commented, “When I\njoined Lifeward, my priority was building the commercial foundation to scale\nthe business: strengthening our reimbursement capabilities, expanding our\ndistribution model and positioning the Company with the capital to execute its\ngrowth strategy. With that foundation in place and delivering results, I have\ndecided to pursue other opportunities. I am proud of what our team\naccomplished and confident Josh, Rami and the Board will build on this\nmomentum.”\n\nHexter brings nearly three decades of leadership, business development,\noperations and management experience in the life sciences industry. His\nexperience includes serving as Chief Operating and Business Officer of Oramed\nPharmaceuticals, Chief Business Officer of BrainsWay, Executive Director of\nCorporate In-Licensing at BioLineRx, and leadership roles in private equity\nand venture capital. He also founded and served as Chief Executive Officer of\nBiosensor Systems Design.\n\n“Lifeward has reached an important point in its development, with the\ncommercial infrastructure, reimbursement foundation and distribution strategy\nin place to support a much larger business,” said Josh Hexter, incoming\nInterim Chief Executive Officer of Lifeward. “Mark built Lifeward’s\ncommercial and reimbursement infrastructure and successfully expanded its\ndistribution model, putting the Company in a strong position to scale from\nhere. My priority as Interim CEO will be to build on the Company’s\nestablished commercial execution strategy and leverage Lifeward’s platform\nacross its growing portfolio of rehabilitation technologies.”\n\nAviram brings a track record of building finance functions at global\ntechnology and medical device companies through periods of growth. He most\nrecently served as Chief Financial Officer of Beewise, a robotics, artificial\nintelligence and computer vision company. He previously served as Chief\nFinancial Officer of ENDYMED Medical and held senior finance leadership\npositions at Syneron-Candela. Aviram is a certified public accountant and\nholds a B.Sc. in Information Systems and Economics and an M.A. in Economics\nfrom the University of Haifa.\n\nAbout Lifeward\n\nLifeward is a global innovator focused on advancing medical technologies and\nbiomedical solutions that improve lives. The Company’s established portfolio\nincludes market-leading neurorehabilitation technologies such as the ReWalk(®\n)Exoskeleton, AlterG(® )Anti-Gravity system, MyoCycle(® )FES System, and\nReStore(® )Exo-Suit. These solutions span the continuum of care in physical\nrehabilitation and recovery, deploying the most advanced robotics and AI\ntechnologies to restore full health and quality of life to a broadening\npatient population. The Company is now executing a strategic evolution into a\ndiversified biomedical company, expanding beyond rehabilitation and into\nhigh-value therapeutic platforms. This includes its Protein Oral Delivery\n(POD™) platform, designed to enable oral delivery of biologic drugs, with\nlead candidate ORMD-0801 (oral insulin) targeting a large and underserved\ndiabetes market.\n\nLifeward has operations in the United States, Israel, and Germany. For more\ninformation on the Lifeward mission and product portfolio, please\nvisit GoLifeward.com\n(https://www.globenewswire.com/Tracker?data=ioeg6IOJEPkYanqwOqbbYPkr0w_8MxAOUSTbXMbnGkECpgnNM0t_Yi7MGS3tXhgHifHCOCtf8HH6o2BSJlwUKw==).\n\nLifeward(®), ReWalk(®), ReStore(® )and AlterG(® )are registered trademarks\nof Lifeward Ltd. and/or its affiliates.\n\nForward-Looking Statements\nIn addition to historical information, this press release contains\nforward-looking statements within the meaning of the U.S. Private Securities\nLitigation Reform Act of 1995, Section 27A of the U.S. Securities Act of\n1933, and Section 21E of the U.S. Securities Exchange Act of 1934. Such\nforward-looking statements may include projections regarding the Company's\nfuture performance and other statements that are not statements of historical\nfact and, in some cases, may be identified by words like \"anticipate,\"\n\"assume,\" \"believe,\" \"continue,\" \"could,\" \"estimate,\" \"expect,\" \"intend,\"\n\"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"future,\" \"will,\" \"should,\"\n\"would,\" \"seek\" and similar terms or phrases. For example, when the Company\ndiscusses its momentum, strategy, potential growth and ability to identify a\npermanent chief executive officer, it is using forward-looking statements. The\nforward-looking statements contained in this press release are based on\nmanagement's current expectations, which are subject to uncertainty, risks and\nchanges in circumstances that are difficult to predict and many of which are\noutside of the Company’s control. Important factors that could cause the\nCompany’s actual results to differ materially from those indicated in the\nforward-looking statements include, among others: management’s expectations,\nhopes, beliefs, intentions or strategies regarding the future including,\nwithout limitation, statements regarding: the future operations of Lifeward,\nincluding research and development activities; the nature, strategy and focus\nof Lifeward; Lifeward’s ability to successfully integrate Oratech\nPharmaceuticals Ltd. into its organization and realize the anticipated\nbenefits therefrom; anticipated clinical drug development activities and\nrelated timelines, and other clinical results; the sufficiency of\npost-transaction resources to support the advancement of Lifeward’s pipeline\nthrough certain milestones and the time period over which Lifeward’s\npost-transaction capital resources will be sufficient to fund its anticipated\noperations; unexpected costs, charges or expenses resulting from the strategic\ntransaction; expected timing and results of the ORMD-0801 clinical trial;\nlegislative, regulatory, political and economic developments; the acceptance\nof the ReWalk 7 Personal Exoskeleton by healthcare professionals and patients;\nuncertainties associated with future clinical trials and the clinical\ndevelopment process, the product development process and FDA regulatory\nsubmission review and approval process; the Company's ability to have\nsufficient funds to meet certain future capital requirements, which could\nimpair the Company's efforts to develop and commercialize existing and new\nproducts; the Company's ability to maintain and grow its reputation and the\nmarket acceptance of its products; the Company's ability to achieve\nreimbursement from third-party payors, including CMS, for its products; the\nCompany's limited operating history and its ability to leverage its sales,\nmarketing and training infrastructure; the Company's expectations as to its\nclinical research program and clinical results; the Company's expectations\nregarding future growth, including its ability to increase sales in its\nexisting geographic markets and expand to new markets; the Company’s ability\nto continue to operate as a going concern; the Company's ability to obtain\ncertain components of its products from third-party suppliers and its\ncontinued access to its product manufacturers; the Company’s ability to\nnavigate any difficulties associated with moving production of its AlterG\nAnti-Gravity Systems to a contract manufacturer and transitioning the\nmanufacturing of its ReWalk products to its in-house manufacturer; the\nCompany's ability to improve its products and develop new products; the\nCompany's compliance with medical device reporting regulations to report\nadverse events involving the Company's products, which could result in\nvoluntary corrective actions or enforcement actions such as mandatory recalls,\nand the potential impact of such adverse events on the Company's ability to\nmarket and sell its products; the Company's ability to gain and maintain\nregulatory approvals; the Company's ability to maintain adequate protection of\nits intellectual property and to avoid violation of the intellectual property\nrights of others; the risk of a cybersecurity attack or breach of the\nCompany's IT systems significantly disrupting its business operations; the\nCompany's ability to use effectively the proceeds of its offerings of\nsecurities; and other factors discussed under the heading \"Risk Factors\" in\nthe Company’s annual report on Form 10-K, as amended, for the year\nended December 31, 2025 filed with the SEC and other documents\nsubsequently filed with or furnished to the SEC. Any forward-looking\nstatement made in this press release speaks only as of the date hereof.\nFactors or events that could cause the Company’s actual results to differ\nfrom the statements contained herein may emerge from time to time, and it is\nnot possible for the Company to predict all of them. Except as required by\nlaw, the Company undertakes no obligation to publicly update any\nforward-looking statements, whether as a result of new information, future\ndevelopments or otherwise.\n\nContact:\nAlmog Adar\nChief Financial Officer\nLifeward\n\nE: media@golifeward.com\nE: ir@golifeward.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/9343d7ac-5bc7-4a60-a2c9-a41bf7b5e007)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-08-31T20:15:00.173759437Z","server_sent_at_ms":1788207300173},"received_at":"2026-08-31T20:15:00.313Z","source_url":"https://www.globenewswire.com/news-release/2026/08/31/3353696/32993/en/lifeward-appoints-josh-hexter-interim-chief-executive-officer-and-rami-aviram-chief-financial-officer.html"},"analysis":{"id":"120456","press_release_id":"131547","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":["CEO departure without named permanent successor (Interim CEO appointed)","Concurrent turnover of CEO and CFO roles"],"eventType":"executive_change","narrative":"Lifeward appointed Josh Hexter as Interim CEO effective September 1, 2026, and Rami Aviram as CFO effective November 1, 2026.\n\nOutgoing CEO Mark Grant is departing to pursue other opportunities but will remain as a consultant through the end of September to assist with the transition.\n\nThe leadership change comes as the company reports strong Q2 momentum, with revenue increasing 16% year-over-year to $6.6 million, driven by 13% growth in ReWalk sales and 25% growth in AlterG revenue.","sentiment":"neutral","agentHooks":{"shouldPost":true,"suggestedAngle":"C-suite shakeup: CEO departs as Lifeward reports 16% revenue growth."},"keyFigures":{"revenue":"$6.6 million","revenueYoy":"16%","customDimensions":{"rewalk_sales_growth":"13%","alterg_revenue_growth":"25%"}},"quotedText":"Mark built Lifeward’s commercial and reimbursement infrastructure and successfully expanded its distribution model, putting the Company in a strong position to scale from here.","namedEntities":{"people":[{"name":"Josh Hexter","role":"Interim Chief Executive Officer"},{"name":"Rami Aviram","role":"Chief Financial Officer"},{"name":"Mark Grant","role":"Outgoing Chief Executive Officer"},{"name":"Avi Gabay","role":"Chairman"}],"products":["ReWalk Personal Exoskeleton","AlterG Anti-Gravity system","MyoCycle FES System","ReStore Exo-Suit","POD platform","ORMD-0801"],"companies":[{"name":"Lifeward","ticker":"LFWD"},{"name":"Oramed Pharmaceuticals"},{"name":"BrainsWay"},{"name":"BioLineRx"},{"name":"Biosensor Systems Design"},{"name":"Beewise"},{"name":"ENDYMED Medical"},{"name":"Syneron-Candela"}],"dollarAmounts":[{"amount":"$6.6 million","context":"Q2 2026 revenue"}]},"materialImpact":{"score":5,"reasoning":"CEO Mark Grant is departing and is being replaced by an interim CEO, Josh Hexter. A new CFO is also being appointed, signaling significant C-suite transition."},"tickerRelevance":{"others":[],"primary":"LFWD"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"executive_change","sectorWeight":"healthcare"}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":5,"narrative":"Lifeward appointed Josh Hexter as Interim CEO effective September 1, 2026, and Rami Aviram as CFO effective November 1, 2026.\n\nOutgoing CEO Mark Grant is departing to pursue other opportunities but will remain as a consultant through the end of September to assist with the transition.\n\nThe leadership change comes as the company reports strong Q2 momentum, with revenue increasing 16% year-over-year to $6.6 million, driven by 13% growth in ReWalk sales and 25% growth in AlterG revenue.","key_figures":{"revenue":"$6.6 million","revenueYoy":"16%","customDimensions":{"rewalk_sales_growth":"13%","alterg_revenue_growth":"25%"}},"named_entities":{"people":[{"name":"Josh Hexter","role":"Interim Chief Executive Officer"},{"name":"Rami Aviram","role":"Chief Financial Officer"},{"name":"Mark Grant","role":"Outgoing Chief Executive Officer"},{"name":"Avi Gabay","role":"Chairman"}],"products":["ReWalk Personal Exoskeleton","AlterG Anti-Gravity system","MyoCycle FES System","ReStore Exo-Suit","POD platform","ORMD-0801"],"companies":[{"name":"Lifeward","ticker":"LFWD"},{"name":"Oramed Pharmaceuticals"},{"name":"BrainsWay"},{"name":"BioLineRx"},{"name":"Biosensor Systems Design"},{"name":"Beewise"},{"name":"ENDYMED Medical"},{"name":"Syneron-Candela"}],"dollarAmounts":[{"amount":"$6.6 million","context":"Q2 2026 revenue"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-31T20:43:01.828Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"executive_change","sectorWeight":"healthcare"}},"durationMs":309793,"modelName":"glm-4.7"}}